|
1
|
Gillen S, Schuster T, Meyer Zum
Büschenfelde C, Friess H and Kleeff J: Preoperative/neoadjuvant
therapy in pancreatic cancer: A systematic review and meta-analysis
of response and resection percentages. PLoS Med. 7:e10002672010.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ishii H, Furuse J, Boku N, Okusaka T,
Ikeda M, Ohkawa S, Fukutomi A, Hamamoto Y, Nakamura K, Fukuda H, et
al: Phase II study of gemcitabine chemotherapy alone for locally
advanced pancreatic carcinoma: JCOG0506. Jpn J Clin Oncol.
40:573–579. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Von Hoff DD, Ramanathan RK, Borad MJ,
Laheru DA, Smith LS, Wood TE, Korn RL, Desai N, Trieu V, Iglesias
JL, et al: Gemcitabine plus nab-paclitaxel is an active regimen in
patients with advanced pancreatic cancer: A phase I/II trial. J
Clin Oncol. 29:4548–5454. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Conroy T, Desseigne F, Ychou M, Bouché O,
Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de
la Fouchardière C, et al: FOLFIRINOX versus gemcitabine for
metastatic pancreatic cancer. N Engl J Med. 364:1817–1825. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wagner M, Redaelli C, Lietz M, Seiler CA,
Friess H and Bűcher MW: Curative resection is the single most
important factor determining outcome in patients with pancreatic
adenocarcinoma. Br J sSurg. 91:586–594. 2004. View Article : Google Scholar
|
|
6
|
Verbeke CS and Menon KV: Redefining
resection margin status in pancreatic cancer. HPB (Oxford).
11:282–289. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nagakawa T, Kurachi M, Konishi K and
Miyazaki I: Translateral retroperitoneal approach in radical
surgery for pancreatic carcinoma. Jpn J Surg. 12:229–33. 1982.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nagakawa T, Nagamori M, Futakami F,
Tsukioka Y, Kayahara M, Ohta T, Ueno K and Miyazaki I: Result of
extensive surgery for pancreatic carcinoma. Cancer. 77:640–645.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kitagawa H, Tajima H, Nakagawara H, Makino
I, Miyashita T, Shoji M, Nakanuma S, Hayashi N, Takamura H, Ohta T
and Ohtake H: En bloc vascular resection for the treatment of
borderline resectable pancreatic head carcinoma. Mol Clin Oncol.
2:369–374. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kitagawa H, Tajima H, Nakagawara H, Makino
I, Miyashita T, Terakawa H, Nakanuma S, Hayashi H, Takamura H and
Ohta T: A modification of radical antegrade modular
pancreato-splenectomy for adenocarcinoma of the left pancreas:
Significance of en bloc resection including the anterior renal
fascia. World J Surg. 38:2448–2454. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nimura Y, Nagino M, Takao S, Takada T,
Miyazaki K, Kawarada Y, Miyagawa S, Yamaguchi A, Ishiyama S, Takeda
Y, et al: Standard versus extended lymphadenectomy in radical
pancreato-duodenectomy for ductal adenocarcinoma of the head of the
pancreas: Long-term results of a Japanese multicenter randomized
controlled trial. J Hepatobiliary Pancreat Sci. 19:230–2341. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Evans DB, Abbruzzese JL and Willett CG:
Cancer of the pancreas. In: DeVita VT, Hellman S and Rosenberg SA
(eds.): Cancer: Priciples and Practice of Oncology. 6th edition.
Philadelphia, Lippincott, Williams and Wilkins. 1:pp1126–1161.
1997.
|
|
13
|
Oettle H, Post S, Neuhaus P, Gellert K,
Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C,
et al: Adjuvant chemotherapy with gemcitabine vs observation in
patients undergoing curative-intent resection of pancreatic cancer:
A randomized controlled trial. JAMA. 297:267–277. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Uesaka K, Boku N, Fukutomi A, Okamura Y,
Konishi M, Matsumoto I, Kaneoka Y, Shimizu Y, Nakamori S, Sakamoto
H, et al: Adjuvant chemotherapy of S-1 versus gemcitabine for
resected pancreatic cancer: A phase 3, open-label, randomised,
non-inferiority trial (JASPAC 01). Lancet. 388:248–257. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Klinlenbijl JH, Jeekel J, Sahmoud T, van
Pel R, Couvreur ML, Veenhof CH, Arnaud JP, Gonzalez DG, de Wit LT,
Hennipman A, et al: Adjuvant radiotherapy and 5-fluorouracil after
curative resection of cancer of the pancreas and periampullary
region: Phase III trial of the EORTC gastrointestinal tract cancer
cooperative group. Ann Surg. 230:776–782. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Spitz FR, Abbruzzese JL, Lee JE, Pisters
PW, Lowy AM, Fenoglio CJ, Cleary KR, Janjan NA, Goswitz MS, Rich
TA, et al: Preoperative and postoperative chemoradiation strategies
in patients treated with pancreaticoduodenectomy for adenocarcinoma
of the pancreas. J Clin Oncol. 15:928–937. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yeo CJ, Abrams RA, Grochow LB, Sohn TA,
Ord SE, Hruban RH, Zahurak ML, Dooley WC, Coleman J, Sauter PK, et
al: Pancreaticoduodenectomy for pancreatic adenocarcinoma:
Postoperative adjuvant chemoradiation improves survival. A
prospective, single-institution experience. Ann Surg. 225:621–633.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lee JL, Kim SC, Kim JH, Lee SS, Kim TW,
Park DH, Seo DW, Lee SK, Kim MH, Kim JH, et al: Prospective
efficacy and safety study of neoadjuvant gemcitabine with
capecitabine combination chemotherapy for borderline-resectable or
unresectable locally advanced pancreatic adenocarcinoma. Surgery.
152:851–862. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Itchins M, Arena J, Nahm CB, Rabindran J,
Kim S, Gibbs E, Bergamin S, Chua TC, Gill AJ, Maher R, et al:
Retrospective cohort analysis of neoadjuvant treatment and survival
in resectable and borderline resectable pancreatic ductal
adenocarcinoma in a high volume referral center. Eur J Surg Oncol.
43:1711–1717. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Katz MH, Shi Q, Ahmad SA, Herman JM, Marsh
Rde W, Collisson E, Schwartz L, Frankel W, Martin R, Conway W, et
al: Preoperative modified FOLFIRINOX treatment followed by
capecitabine-based chemoradiation for borderline resectable
pancreatic cancer: Alliance for clinical trials in oncology Trial
A021101. JAMA Surg. 151:e1611372016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shubert CR, Bergquist JR, Groeschl RT,
Habermann EB, Wilson PM, Truty MJ, Smoot RL, Kendrick ML, Nagorney
DM and Farnell MB: Overall survival is increased among stage III
pancreatic adenocarcinoma patients receiving neoadjuvant
chemotherapy compared to surgery first and adjuvant chemotherapy:
An intention to treat analysis of the National Cancer Database.
Surgery. 160:1080–1096. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nagakawa Y, Hosokawa Y, Nakayama H, Sahara
Y, Takishita C, Nakajima T, Hijikata Y, Kasuya K, Katsumata K,
Tokuuye K and Tsuchida A: A phase II trial of neoadjuvant
chemoradiotherapy with intensity-modulated radiotherapy combined
with gemcitabine and S-1 for borderline-resectable pancreatic
cancer with arterial involvement. Cancer Chemother Pharmacol.
79:951–957. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tajima H, Ohta T, Kitagawa H, Okamoto K,
Sakai S, Makino I, Kinoshita J, Furukawa H, Nakamura K, Hayashi H,
et al: Pilot study of neoadjuvant chemotherapy with gemcitabine and
oral S-1 for resectable pancreatic cancer. Exp Ther Med. 3:787–792.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tajima H, Kitagawa H, Tsukada T, Nakanuma
S, Okamoto K, Sakai S, Makino I, Furukawa H, Nakamura K, Hayashi H,
et al: A phase I study of neoadjuvant chemotherapy with gemcitabine
plus oral S-1 for resectable pancreatic cancer. Mol Clin Oncol.
1:768–772. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Therasse P, Arbuck SG, Eisenhauer EA,
Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van
Oosterom AT, Christian MC and Gwyther SG: New guidelines to
evaluate the response to treatment in solid tumors. J Natl Cancer
Inst. 92:205–216. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Makino I, Kitagawa H, Ohta T, Nakagawara
H, Tajima H, Ohnishi I, Takamura H, Tani T and Kayahara M: Nerve
plexus invasion in pancreatic cancer. Spread patterns on
histopathologic and embryological analysis. Pancreas. 37:358–365.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Evans DB, Rich TA, Byrd DR, Cleary KR,
Connelly JH, Levin B, Charnsangavej C, Fenoglio CJ and Ames FC:
Preoperative chemoradiation and pancreaticoduodenectomy for
adenocarcinoma of the pancreas. Arch Surg. 127:1335–1339. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Esposito I, Kleeff J, Bergmann F, Reiser
C, Herpel E, Friess H, Schirmacher P and Büchler MW: Most
pancreatic cancer resections are R1 resections. Ann Surg Oncol.
15:1651–1660. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Terakawa H, Kitagawa H, Makino I, Hayashi
H, Oyama K, Nakagawara H, Miyashita T, Tajima H, Takamura H,
Fushida S, et al: Location of the meso-pancreatoduodenum as a
regional lymphatic basin for pancreatic head carcinoma. Oncol Lett.
14:397–403. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tajima H, Ohta T, Kitagawa H, Sakai S,
Makino I, Hayashi H, Nakagawara H, Onishi I, Takamura H, Ninomiya
I, et al: Hepatic arterial infusion chemotherapy for post-operative
liver metastases from pancreatic cancer in a patient with
leukocytopenia: A case report. Exp Ther Med. 1:987–990. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tajima H, Ohta T, Kitagawa H, Sakai S,
Makino I, Hayashi H, Oyama K, Nakagawara H, Fujita H, Onishi I, et
al: Pilot study of hepatic arterial infusion chemotherapy with
gemcitabine and 5-fluorouracil for patients with postoperative
liver metastases from pancreatic cancer. Exp Ther Med. 2:265–269.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tajima H, Kitagawa H, Tsukada T, Okamoto
K, Nakanuma SI, Sakai S, Makino I, Furukawa H, Hayashi H, Oyama Ku,
et al: Hepatic arterial infusion chemotherapy with gemcitabine and
5-fluorouracil or oral S-1 improves the prognosis of patients with
postoperative liver metastases from pancreatic cancer. Mol Clinic
Oncol. 1:869–874. 2013. View Article : Google Scholar
|
|
33
|
Satoi S, Yamaue H, Kato K, Takahashi S,
Hirono S, Takeda S, Eguchi H, Sho M, Wada K, Shinchi H, et al: Role
of adjuvant surgery for patients with initially unresectable
pancreatic cancer with a long-term favorable response to
non-surgical anti-cancer treatments: Results of a project study for
pancreatic surgery by the Japanese society of
hepato-biliary-pancreatic surgery. J Hepatobiliary Pancreat Sci.
20:590–600. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Eguchi H, Yamada D, Iwagami Y, Gotoh K,
Kawamoto K, Wada H, Asaoka T, Noda T, Takeda Y, Tanemura M, et al:
Prolonged neoadjuvant therapy for locally advanced pancreatic
cancer. Dig Surg. 35:70–76. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Valle S, Martin-Hijano L, Alcalá S,
Alonso-Nocelo M and Sainz B Jr: The ever-evolving concept of the
cancer stem cell in pancreatic cancer. Cancers (Basel). 10(pii):
E332018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tsubouchi K, Minami K, Hayashi N, Yokoyama
Y, Mori S, Yamamoto H and Koizumi M: The CD44 standard isoform
contributes to radioresistance of pancreatic cancer cells. J Radiat
Res. 58:816–826. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yang AD, Fan F, Camp ER, van Buren G, Liu
W, Somcio R, Gray MJ, Cheng H, Hoff PM and Ellis LM: Chronic
oxaliplatin resistance induces epithelial-mesenchymal transition in
colorectal cancer cell lines. Clin Cancer Res. 12:4147–4153. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Tsukamoto H, Shibata K, Kajiyama H,
Terauchi M, Nawa A and Kikkawa F: Irradiation-induced
epithelial-mesencymal transition (EMT) related to invasive
potential in endometrial carcinoma cells. Gynecol Oncol.
107:500–504. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Tajima H, Ohta T, Makino I, Hayashi H,
Nakagawara H, Onishi I, Takamura H, Ninomiya I, Kitagawa H, Fushida
S, et al: Expression of epithelial-mesenchymal transition markers
in locally recurrent hepatocellular carcinoma after radiofrequency
ablation. Exp Therap Med. 1:347–350. 2010. View Article : Google Scholar
|
|
40
|
Tajima H, Ohta T, Kitagawa H, Okamoto K,
Sakai S, Kinoshita J, Makino I, Furukawa H, Hayashi H, Nakamura K,
et al: Neoadjuvant chemotherapy with gemcitabine for pancreatic
cancer increases in situ expression of the apoptosis marker M30 and
stem cell marker CD44. Oncol Lett. 3:1186–1190. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhang D, Sun L, Xian W, Liu F, Ling G,
Xiao L, Liu Y, Peng Y, Haruna Y and Kanwar YS: Low-dose paclitaxel
ameliorates renal fibrosis in rat UUO model by inhibition of
TGF-beta/Smad activity. Lab Invest. 90:436–447. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhou J, Zhong DW, Wang QW, Miao XY and Xu
XD: Paclitaxel ameliorates fibrosis in hepatic stellate cells via
inhibition of TGF-beta/Smad activity. World J Gastroenterol.
16:3330–3334. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Choi HS, Savard CE, Choi JW, Kuver R and
Lee SP: Paclitaxel interrupts TGF-beta1 signaling between
gallbladder epithelial cells and myofibroblasts. J Surg Res.
141:183–191. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Hirose A, Tajima H, Ohta T, Tsukada T,
Okamoto K, Nakanuma S, Sakai S, Kinoshita J, Makino I, Furukawa H,
et al: Low-dose paclitaxel inhibits the induction of
epidermal-mesenchymal transition in the human cholangiocarcinoma
CCKS-1 cell line. Oncol Lett. 6:915–920. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Cufí S, Vazquez-Martin A,
Oliveras-Ferraros C, Martin-Castillo B, Joven J and Menendez JA:
Metformin against TGFβ-induced epithelial-to- mesenchymal
transition (EMT): From cancer stem cells to aging-associated
fibrosis. Cell Cycle. 9:4461–4468. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Vazquez-Martin A, Oliveras-Ferraros C,
Cufí S, Del Barco S, Martin-Castillo B and Menendez JA: Metformin
regulates breast cancer stem cell ontogeny by transcriptional
regulation of the epithelial-mesenchymal transition (EMT) status.
Cell Cycle. 9:3807–3814. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Del Barco S, Vazquez-Martin A, Cufí S,
Oliveras-Ferraros C, Bosch-Barrera J, Joven J, Martin-Castillo B
and Menendez JA: Metformin: Multi-faceted protection against
cancer. Oncotarget. 2:896–917. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Okamoto K, Tajima H, Ohta T, Nakanuma S,
Hayashi H, Nakagawara H, Onishi I, Takamura H, Ninomiya I, Kitagawa
H, et al: Angiotensin II induces tumor progression and fibrosis in
intrahepatic cholangiocarcinoma through an interaction with hepatic
stellate cells. Int J Oncol. 37:1251–1259. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Okazaki M, Fushida S, Harada S, Tsukada T,
Kinoshita J, Oyama K, Tajima H, Ninomiya I, Fujimura T and Ohta T:
The angiotensin II type 1 receptor blocker candesartan suppresses
proliferation and fibrosis in gastric cancer. Cancer Lett.
355:46–53. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Chang TI, Kang HY, Kim KS, Lee SH, Nam BY,
Paeng J, Kim S, Park JT, Yoo TH, Kang SW and Han SH: The effect of
statin on epithelial-mesenchymal transition in peritoneal
mesothelial cells. PLoS One. 9:e1096282014. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Yang T, Chen M and Sun T: Simvastatin
attenuates TGF-β1-induced epithelial-mesenchymal transition in
human alveolar epithelial cells. Cell Physiol Biochem. 31:863–874.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Shoji M, Ninomiya I, Makino I, Kinoshita
J, Nakamura K, Oyama K, Nakagawara H, Fujita H, Tajima H, Takamura
H, et al: Valproic acid, a histone deacetylase inhibitor, enhances
radiosensitivity in esophageal squamous cell carcinoma. Int J
Oncol. 40:2140–2146. 2012.PubMed/NCBI
|
|
53
|
Watanabe T, Tajima H, Hironori H,
Nakagawara H, Ohnishi I, Takamura H, Ninomiya I, Kitagawa H,
Fushida S, Tani T, et al: Sodium valproate blocks the transforming
growth factor (TGF)-β1 autocrine loop and attenuates the
TGF-β1-induced collagen synthesis in a human hepatic stellate cell
line. Int J Mol Med. 28:919–925. 2011.PubMed/NCBI
|
|
54
|
Sun JD, Liu Q, Ahluwalia D, Li W, Meng F,
Wang Y, Bhupathi D, Ruprell AS and Hart CP: Efficacy and safety of
the hypoxia-activated prodrug TH-302 in combination with
gemcitabine and nab-paclitaxel in human tumor xenograft models of
pancreatic cancer. Cancer Biol Ther. 16:438–449. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Zhang D, Yang R, Wang S and Dong Z:
Paclitaxel: New uses for an old drug. Drug Des Devel Ther.
8:279–284. 2014.PubMed/NCBI
|
|
56
|
Meng H, Wang M, Liu H, Liu X, Situ A, Wu
B, Ji Z, Chang CH and Nel AE: Use of a lipid-coated mesoporous
silica nanoparticle platform for synergistic gemcitabine and
paclitaxel delivery to human pancreatic cancer in mice. ACS Nano.
9:3540–3557. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Oettle H: Progress in the knowledge and
treatment of advanced pancreatic cancer: From benchside to bedside.
Cancer Treat Rev. 40:1039–1047. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Miyashita T, Tajima H, Makino I, Okazaki
M, Yamaguchi T, Ohbatake Y, Nakanuma S, Hayashi H, Takamura H,
Ninomiya I, et al: Neoadjuvant chemotherapy with gemcitabine plus
nab-paclitaxel reduces the number of cancer-associated fibroblasts
through depletion of pancreatic stroma. Anticancer Res. 38:337–343.
2018.PubMed/NCBI
|
|
59
|
Waraya M, Yamashita K, Katagiri H, Ishii
K, Takahashi Y, Furuta K and Watanabe M: Preoperative serum CA19-9
and dissected peripancreatic tissue margin as determiners of
long-term survival in pancreatic cancer. Ann Surg Oncol.
16:1231–1240. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Ueda M, Endo I, Nakashima M, Minami Y,
Takeda K, Matsuo K, Nagano Y, Tanaka K, Ichikawa Y, Togo S, et al:
Prognostic factors after resection of pancreatic cancer. World J
Surg. 33:104–110. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Hosokawa Y, Nagakawa Y, Sahara Y,
Takishita C, Katsumata K and Tsuchida A: Serum SPan-1 is a
significant risk factor for early recurrence of pancreatic cancer
after curative resection. Dig Surg. 34:125–132. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Shimizu T, Asakuma M, Tomioka A, Inoue Y,
Hirokawa F, Hayashi M and Uchiyama K: Span-1 and CA19-9 as
predictors of early recurrence and lymph node metastasis for
patients with invasive pancreatic cancer after pancreatectomy. Am
Surg. 84:109–113. 2018.PubMed/NCBI
|
|
63
|
Kurahara H, Maemura K, Mataki Y, Sakoda M,
Iino S, Kawasaki Y, Arigami T, Mori S, Kijima Y, Ueno S, et al: A
Therapeutic strategy for resectable pancreatic cancer based on risk
factors of early recurrence. Pancreas. 47:753–758. 2018.PubMed/NCBI
|
|
64
|
Berge AC, Meszoely IM, Ross EA, Watson JC
and Hoffman JP: Undetectable preoperative levels of serum CA 19-9
correlate with improved survival for patients with resectable
pancreatic adenocarcinoma. Ann Surg Oncol. 11:644–649. 2004.
View Article : Google Scholar : PubMed/NCBI
|
